Korro Bio Inc. Common Stock (KRRO)

FairStock Score: 25/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money, have durable competitive advantages, and can be bought at a sensible price. Korro Bio fails the first test. In fiscal 2025, the year ended 2025-12-31, revenue was $6.4 million while net loss was $117.3 million. In fiscal 2024, the year ended 2024-12-31, revenue was $2.3 million and net loss was $83.6 million. The company has lost money in each of the last four years, which is why the FairStock Lynch category is none. Trailing free cash flow is -$68.3 million, a -52.6% FCF yield on a $129.7 million market cap. ROE is -97.69%, ROCE is -27.95%, Piotroski is 3/9, and Altman Z is -1.85. Debt/equity of 0.41 is not alarming by itself, but the cash burn is. The RNA editing platform and KRRO-121 for hyperammonemia could be valuable if clinical data succeed, but I cannot underwrite a moat from a platform alone. Competition, regulation, and financing risk are real. At the 2026-10-13 close of $8.81, FairStock calculates P/E at -0.89 and P/B at 1.25. The P/B looks modest, but book value can be consumed by losses. Beta of 2.25 and a 52-week range of $5.20 to $55.89 show how speculative the stock is. The FairStock Score is 25/100. This is not a Graham net-net or a Buffett compounder; it is closer to a venture-like option on science. I would need proof of durable cash flows and a much clearer path to profitability before calling it an investment rather than a wager.

In plain English: Korro Bio is a small biotech company trying to develop medicines that edit RNA to treat rare diseases. The business is not profitable, brings in very little revenue, and has been losing large amounts of money. At $8.81, the shares may look cheaper than the past year high, but based on its current numbers the price is not obviously cheap; it depends on risky future science.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer